PubMed

Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection.

Katlama C, Valantin MA, Matheron S, Coutellier A, Calvez V, Descamps D, Longuet C, Bonmarchand M, Tubiana R, De Sa M, Lancar R, Agut H, Brun-Vezinet F, Costagliola D.

Ann Intern Med. 1998 Oct 1;129(7):525-31.PMID: 9758571 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.

Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P.

Antivir Ther. 2005;10(8):911-6.PMID: 16430196 [PubMed - indexed for MEDLINE]Related articles

A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).

Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R, Stevens M.

AIDS. 2000 Jul 28;14(11):1591-600.PMID: 10983646 [PubMed - indexed for MEDLINE]Related articles

An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.

Foudraine NA, de Jong JJ, Jan Weverling G, van Benthem BH, Maas J, Keet IP, Jurriaans S, Roos MT, Vandermeulen K, de Wolf F, Lange JM.

AIDS. 1998 Aug 20;12(12):1513-9.PMID: 9727573 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group.

Rockstroh JK, Bergmann F, Wiesel W, Rieke A, Thiesen A, Fätkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H.

AIDS. 2000 Jun 16;14(9):1181-5.PMID: 10894282 [PubMed - indexed for MEDLINE]Related articles

A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).

Eron JJ Jr, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R, Stevens M.

AIDS. 2000 Jul 28;14(11):1601-10.PMID: 10983647 [PubMed - indexed for MEDLINE]Related articles

Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).

Joly V, Flandre P, Meiffredy V, Brun-Vezinet F, Gastaut JA, Goujard C, Remy G, Descamps D, Ruffault A, Certain A, Aboulker JP, Yeni P; Novavir Study Group.

Antimicrob Agents Chemother. 2002 Jun;46(6):1906-13.PMID: 12019107 [PubMed - indexed for MEDLINE]Related articlesFree article

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, White AC Jr, Benson C, Thompson M, Kessler HA, Hammer S, Bertz R, Hsu A, Japour A, Sun E.

AIDS. 2001 Jan 5;15(1):F1-9.PMID: 11192874 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.

Duvivier C, Myrto A, Marcelin AG, Ghosn J, Ait-Mohand H, Schneider L, Agher R, Bricaire F, Costagliola D, Calvez V, Peytavin G, Katlama C.

Antivir Ther. 2003 Dec;8(6):603-9.PMID: 14760894 [PubMed - indexed for MEDLINE]Related articles

A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects.

Staszewski S, Katlama C, Harrer T, Massip P, Yeni P, Cutrell A, Tortell SM, Harrigan RP, Steel H, Lanier RE, Pearce G.

AIDS. 1998 Nov 12;12(16):F197-202.PMID: 9833847 [PubMed - indexed for MEDLINE]Related articles

Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team.

Mobley JE, Pollard RB, Schrader S, Adler MH, Kelleher T, McLaren C.

AIDS. 1999 Jul 30;13(11):F87-93.PMID: 10449279 [PubMed - indexed for MEDLINE]Related articles

Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.

Raffi F, Reliquet V, Francois C, Garre M, Hascoet C, Allavena C, Arvieux C, Breux JP, Perre P, Rozenbaum W, Auger S.

Antivir Ther. 1998;3 Suppl 4:57-60.PMID: 10723512 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients.

Raffi F, Reliquet V, Auger S, Besnier JM, Chennebault JM, Billaud E, Michelet C, Perre P, Lafeuillade A, May T, Billaudel S.

AIDS. 1998 Oct 22;12(15):1999-2005.PMID: 9814868 [PubMed - indexed for MEDLINE]Related articles

Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.

Idigbe EO, Adewole TA, Eisen G, Kanki P, Odunukwe NN, Onwujekwe DI, Audu RA, Araoyinbo ID, Onyewuche JI, Salu OB, Adedoyin JA, Musa AZ.

J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):65-9.PMID: 16123684 [PubMed - indexed for MEDLINE]Related articles

The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials.

Eron JJ Jr.

AIDS. 1996 Dec;10 Suppl 5:S11-9.PMID: 9030391 [PubMed - indexed for MEDLINE]Related articles

Pilot study of zidovudine-lamivudine combination therapy in vertically HIV-infected antiretroviral-naive children.

Horneff G, Adams O, Wahn V.

AIDS. 1998 Mar 26;12(5):489-94.PMID: 9543447 [PubMed - indexed for MEDLINE]Related articles

Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.

Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S.

J Med Assoc Thai. 2004 Jul;87(7):760-7.PMID: 15521230 [PubMed - indexed for MEDLINE]Related articles

The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.

Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T.

Clin Ther. 1999 Nov;21(11):1853-63.PMID: 10890257 [PubMed - indexed for MEDLINE]Related articles

Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.

Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM; ALBI (ANRS 070) Study Group.

Antivir Ther. 1999;4 Suppl 3:71-4.PMID: 16021874 [PubMed - indexed for MEDLINE]Related articles

A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.

Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG, Williams VC, Shaefer MS, Pakes GE, Pappa KA; ESS40002 Study Team.

HIV Med. 2006 Mar;7(2):85-98.PMID: 16420253 [PubMed - indexed for MEDLINE]Related articles